These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33832949)

  • 1. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Li D; Chi Y; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Zheng X; Tang P; Gao M
    Clin Cancer Res; 2021 Jul; 27(13):3567-3575. PubMed ID: 33832949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
    Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
    Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 5. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
    Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
    JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
    Leboulleux S; Kapiteijn E; Litière S; Schöffski P; Godbert Y; Rodien P; Jarzab B; Salvatore D; Zanetta S; Capdevila J; Bastholt L; De La Fouchardiere C; Lalami Y; Bardet S; Cornélis F; Dedecjus M; Links T; Sents W; Schlumberger M; Locati DL; Newbold K
    Front Endocrinol (Lausanne); 2024; 15():1403687. PubMed ID: 39015176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial.
    Chi Y; Zheng X; Zhang Y; Shi F; Cheng Y; Guo Z; Ge M; Qin J; Zhang J; Li Z; Zhou X; Huang R; Chen X; Liu H; Cheng R; Xu Z; Li D; Tang P; Gao M
    Clin Cancer Res; 2023 Oct; 29(20):4047-4056. PubMed ID: 37594724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.
    Huang NS; Wei WJ; Xiang J; Chen JY; Guan Q; Lu ZW; Ma B; Sun GH; Wang YL; Ji QH; Wang Y
    Thyroid; 2021 Dec; 31(12):1808-1813. PubMed ID: 34610756
    [No Abstract]   [Full Text] [Related]  

  • 10. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
    Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
    Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
    Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
    Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
    Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
    Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
    Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
    Shen G; Zheng F; Ren D; Du F; Dong Q; Wang Z; Zhao F; Ahmad R; Zhao J
    J Hematol Oncol; 2018 Sep; 11(1):120. PubMed ID: 30231931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
    Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
    Cheng Y; Wang Q; Li K; Shi J; Liu Y; Wu L; Han B; Chen G; He J; Wang J; Lou D; Yu H; Wang S; Qin H; Li X
    Br J Cancer; 2021 Aug; 125(3):366-371. PubMed ID: 34006926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study.
    Zhao J; Chi Y; Hu C; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Li D; Tang P; Gao M; Zheng X
    Front Oncol; 2022; 12():852032. PubMed ID: 36483043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
    Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
    Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
    Wells SA; Robinson BG; Gagel RF; Dralle H; Fagin JA; Santoro M; Baudin E; Elisei R; Jarzab B; Vasselli JR; Read J; Langmuir P; Ryan AJ; Schlumberger MJ
    J Clin Oncol; 2012 Jan; 30(2):134-41. PubMed ID: 22025146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.